[Indications and current development of new targeted therapies in pediatric oncology]

Bull Cancer. 2011 May;98(5):527-39. doi: 10.1684/bdc.2011.1358.
[Article in French]

Abstract

Progresses performed in pediatric oncology during the last 30 years allowed to obtain about 70 to 80% healing rates. These progresses are the result of the optimization of the cytotoxic chemotherapies protocols used at standard and high doses, as well as the improvement of the local treatment. Most of the new anticancer treatments currently in developmental stage are based on targeted therapies, acting against numerous tumor cell abnormalities, like growth factors et their receptors, cell proliferation-inducing factors, molecules involved in DNA repair, cell death inducers, tumor invasion and angiogenesis. They are widely used in adult patients since 10 years and they are being more and more employed in children with cancer. The aim of this article is to review the main indications of these new targeted drugs in pediatric oncology and the new developments of these drugs.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Benzenesulfonates / therapeutic use
  • Bevacizumab
  • Child
  • Dasatinib
  • Erlotinib Hydrochloride
  • Hedgehog Proteins / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate
  • Indoles / therapeutic use
  • Integrins / antagonists & inhibitors
  • Molecular Targeted Therapy / methods*
  • Neoplasms / drug therapy*
  • Niacinamide / analogs & derivatives
  • Nifurtimox / therapeutic use
  • Phenylurea Compounds
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyridines / therapeutic use
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Quinazolines / therapeutic use
  • Sorafenib
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Thiazoles / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzamides
  • Benzenesulfonates
  • Hedgehog Proteins
  • Indoles
  • Integrins
  • Phenylurea Compounds
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrimidines
  • Pyrroles
  • Quinazolines
  • Thiazoles
  • Niacinamide
  • Bevacizumab
  • Imatinib Mesylate
  • Sorafenib
  • Erlotinib Hydrochloride
  • Protein-Tyrosine Kinases
  • TOR Serine-Threonine Kinases
  • nilotinib
  • Nifurtimox
  • Dasatinib
  • Sunitinib